stockrow
Monday 9 November 2026
Export BCYC’s income statement to Excel — free account
Bicycle Therapeutics PLC Sponsored ADR
BCYCBicycle Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $72.6 million, up 105.8% from fiscal 2024.
- Revenue
- +190.2%
- EPS
- +82.4%
- Free cash flow
- +43.5%
Quarter to September 2026, against a year earlier
3.61
0.13
+3.74%
Follow BCYC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | 2 | 7 | 14 | 10 | 12 | 14 | 27 | 35 | 73 | 84 | +56.1% | 38 | 7 | 19 | (35.5%) | |
| Gross margin, % | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | (14) | (16) | (22) | (31) | (52) | (68) | (114) | (179) | (174) | (219) | (139) | +36.2% | ||||||
| EBT margin, % | 0.00 | (790.39) | (311.69) | (223.62) | (497.92) | (585.47) | (789.88) | (664.32) | (492.69) | (301.45) | (166.52) | (301.4) pt | ||||||
| Net income | (14) | (16) | (22) | (31) | (51) | (67) | (113) | (181) | (169) | (219) | (142) | +36.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 6.18 | 16.26 | 1.25 | 0.54 | 0.47 | 0.49 | 0.76 | 0.61 | 1.05 | 1.19 | n/m | |||||
| Earnings | — | (48.81) | (49.78) | (2.77) | (2.66) | (2.67) | (3.80) | (5.08) | (2.90) | (3.16) | (2.03) | (29.0%) | ||||||
| Cash flow | 0.00 | (4.25) | (59.42) | (2.59) | (0.93) | (0.59) | (2.90) | (1.70) | (2.83) | (3.60) | (2.50) | n/m | ||||||
| Capex | 0.00 | (3.34) | (2.70) | (0.14) | (0.06) | (0.08) | (0.64) | (0.08) | (0.02) | (0.03) | (0.03) | n/m | ||||||
| Free cash flow | 0.00 | (7.59) | (62.12) | (2.73) | (0.99) | (0.67) | (3.54) | (1.79) | (2.85) | (3.64) | (2.53) | n/m | ||||||
| Book value | 0.00 | (141.65) | (159.09) | 8.44 | 4.99 | 13.82 | 9.13 | 10.42 | 13.62 | 8.80 | 7.22 | n/m | ||||||
| Shares, m | — | 0 | 0 | 11 | 19 | 25 | 30 | 36 | 58 | 69 | 70 | +94.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | 0.93 | 0.93 | 7.55 | 33.08 | 130.42 | 61.52 | 29.00 | 23.10 | 6.76 | 3.02 | 32.6 | ||||||
| P/B | — | 0.00 | 0.00 | 1.12 | 3.60 | 4.41 | 3.29 | 2.11 | 1.03 | 0.80 | 0.50 | 1.8 | ||||||
| EV/Sales | — | (4.61) | (4.61) | 1.01 | 21.47 | 95.67 | 40.39 | 10.79 | (1.30) | (1.61) | (2.35) | 17.5 | ||||||
| EV/FCF | — | 1.95 | 1.95 | (0.46) | (11.75) | (66.52) | (5.56) | (4.58) | 0.28 | 0.46 | 1.11 | (9.4) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (11) | (1) | (26) | (29) | (18) | (15) | (86) | (61) | (165) | (250) | (175) | +41.1% | |||||
| Capex | 0 | (1) | (1) | (2) | (1) | (2) | (19) | (3) | (1) | (2) | (2) | +28.7% | ||||||
| Free cash flow | (11) | (3) | (27) | (30) | (19) | (17) | (105) | (64) | (166) | (252) | (177) | +41.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 7 | 62 | 68 | 95 | 133 | 422 | 316 | 492 | 861 | 626 | 493 | +63.6% | |||||
| Net debt | (9) | (68) | (63) | (91) | (121) | (409) | (309) | (496) | (880) | (628) | (470) | +59.5% | ||||||
| Shareholders’ equity | 8 | (47) | (70) | 93 | 95 | 346 | 271 | 371 | 793 | 610 | 505 | +61.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (31.48) | (37.88) | (28.07) | (31.91) | (37.60) | (20.85) | (25.32) | (35.92) | (21.78) | (26.15) | (21.30) | +5.3 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | (704.84) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (279.76) | 0.0 pt | ||||||
| ROE | 33.37 | 40.16 | 37.34 | (261.92) | (54.08) | (30.25) | (36.53) | (56.31) | (29.04) | (31.21) | (25.24) | (64.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 61 | 72 | 87 | 119 | 236 | 284 | 305 | 288 | — | +24.8% | |||||
| Revenue/emp, $m | — | 0.00 | 0.12 | 0.19 | 0.12 | 0.10 | 0.06 | 0.09 | 0.12 | 0.25 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026
Bicycle Therapeutics PLC Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TRDA Entrada Therapeutics, Inc. | $191.5M | — (loss-making) | — (loss-making) | −43.93% (below 0%: shrinking) | n/m | −7.05% (below 0%: shrinking) | 100.00% | (4,606.52%) | Compare |
| CGEN Compugen Ltd. | $185.7M | 5.2× | — (loss-making) | +107.00% (above 0%: growing) | n/m | −155.42% (below 0%: shrinking) | (3.54%) | (339.62%) | Compare |
| MDWD MediWound Ltd. | $184.0M | — (loss-making) | — (loss-making) | −45.83% (below 0%: shrinking) | n/m | −49.90% (below 0%: shrinking) | 10.90% | (305.89%) | Compare |
| BCYC Bicycle Therapeutics PLC Sponsored ADR | $182.5M | — (loss-making) | — (loss-making) | +190.24% (above 0%: growing) | n/m | +43.48% (above 0%: growing) | 100.00% | (39.57%) | |
| ACOG Alpha Cognition Inc. | $180.5M | — (loss-making) | — (loss-making) | +267.56% (above 0%: growing) | n/m | −109.25% (below 0%: shrinking) | 94.80% | (127.29%) | Compare |
| WHWK Whitehawk Therapeutics, Inc. | $178.4M | — (loss-making) | — (loss-making) | +33.48% (above 0%: growing) | n/m | +72.57% (above 0%: growing) | 89.36% | 0.00% | Compare |
| UPB Upstream Bio, Inc. | $176.9M | — (loss-making) | — (loss-making) | −17.50% (below 0%: shrinking) | n/m | +9.33% (above 0%: growing) | 100.00% | (5,480.98%) | Compare |
| IVVD Invivyd, Inc. | $166.0M | — (loss-making) | — (loss-making) | +21.20% (above 0%: growing) | n/m | −226.89% (below 0%: shrinking) | 91.09% | (320.76%) | Compare |
| BBOT BridgeBio Oncology Therapeutics, Inc | $163.6M | — (loss-making) | — | — | n/m | −88.78% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $179.5M | — | — | +21.20% | — | −69.34% | 91.09% | (313.32%) |
Pay and ownership Proxy statement filed 22 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 6.34m | 1.93m | 23.92 |
| 2024 | 4.86m | 3.33m | 47.30 |
| 2023 | 5.54m | 625.07k | 61.08 |
Ownership
Directors and executive officers, together
22.00%
Entities affiliated with Baker Bros. Advisors LP
21.70%
Felix J. Baker, Ph.D.
21.70%
Forbion Growth Opportunities Fund II Cooperatief U.A.
6.90%
Armistice Capital, LLC
6.40%
Entities affiliated with Invus Public Equities, L.P.
6.30%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement